As a potential treatment of COVID-19: Montelukast

Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41712

Registro completo de metadados

Campo DC	Valor	Idioma
dc.creator	Fidan, Cihan	-
dc.creator	Aydoğdu, Ayşe	-
dc.date.accessioned	2020-07-03T20:04:57Z	-
dc.date.available	2020-07-03T20:04:57Z	-
dc.date.issued	2020-09	-
dc.identifier.citation	FIDAN, C.; AYDOĞDU, A. As a potential treatment of COVID-19: Montelukast. Medical Hypotheses, [S.l.], v. 142, Sept. 2020.	pt_BR
dc.identifier.uri	https://www.sciencedirect.com/science/article/pii/S0306987720306368	pt_BR
dc.identifier.uri	http://repositorio.ufla.br/jspui/handle/1/41712	-
dc.description.abstract	It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.	pt_BR
dc.language	en_US	pt_BR
dc.publisher	Elsevier	pt_BR
dc.rights	restrictAccess	pt_BR
dc.source	Medical Hypotheses	pt_BR
dc.title	As a potential treatment of COVID-19: Montelukast	pt_BR
dc.type	Artigo	pt_BR
Aparece nas coleções:	FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:

Não existem arquivos associados a este item.